Oramed Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oramed Pharmaceuticals Inc. on June 25, 2019, covering events occurring on June 25, 2019, and July 1, 2019. The filing addresses changes to the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: On June 25, 2019, Mrs. Xiaopeng Li resigned from the Board of Directors effective immediately for personal reasons. She reported no disagreement with the Company regarding operations, policies, or practices.
- Appointment: On July 1, 2019, the Board appointed Mr. Xiaoming Gao to fill the vacancy left by Mrs. Li. Mr. Gao will not serve on any Board committees.
Management Commentary and Background
Mr. Xiaoming Gao brings over 30 years of experience in the insulin industry, including responsibility for introducing Novo Nordisk insulin to China. He founded Hefei Tianmai Biotechnology development Co., Ltd. in 2007 and serves as chairman of a Technology License Agreement with Hefei Tianhui Incubator of Technologies Co. Ltd.
Regarding compensation, Mr. Gao will receive fees identical to other non-executive directors as outlined in the Company's 2018 Form 10-K. The Company expects to execute a standard indemnification agreement with him on terms consistent with those of other directors and officers.
Key Facts for Investor Verification
- Confirm the effective date of Mrs. Li's resignation (June 25, 2019) and Mr. Gao's appointment (July 1, 2019).
- Verify Mr. Gao's specific background in the insulin industry and his role with Hefei Tianmai Biotechnology.
- Review the Company's 2018 Form 10-K to confirm the standard director fee structure applicable to Mr. Gao.
- Note that no disagreements were cited regarding the resignation of the departing director.